Results 161 to 170 of about 14,776 (215)

Novel anti-ITGA4 monoclonal antibody induces cell death via large pore formation in NK/T-cell lymphoma cells. [PDF]

open access: yesSci Rep
Takeuchi S   +20 more
europepmc   +1 more source

Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer <i>via</i> ZFP91. [PDF]

open access: yesFront Oncol
Song L   +12 more
europepmc   +1 more source

Cucurbitacin B Exhibits Antitumor Effects on Chordoma Cells via Disruption of Brachyury. [PDF]

open access: yesInt J Mol Sci
Seeling C   +7 more
europepmc   +1 more source

Correction: Salehi et al. <i>Cucurbits</i> Plants: A Key Emphasis to Its Pharmacological Potential. <i>Molecules</i> 2019, <i>24</i>, 1854. [PDF]

open access: yesMolecules
Salehi B   +23 more
europepmc   +1 more source

Hu-lu-su-pian ameliorates hepatic steatosis by regulating CIDEA expression in AKT-driven MASLD mice. [PDF]

open access: yesFront Pharmacol
Ren R   +10 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Cucurbitacin B and cucurbitacin I suppress adipocyte differentiation through inhibition of STAT3 signaling

Food and Chemical Toxicology, 2014
Cucurbitacin B, a member of the cucurbitaceae family, can act as a STAT3 signaling inhibitor to regulate the growth of hepatocellular carcinoma. STAT3 signaling has been shown to inhibit adipocyte differentiation through C/EBPα and PPARγ. Based on these studies, we hypothesized that cucurbitacin B would prevent PPARγ mediated adipocyte differentiation ...
Dong Kwon Yang   +2 more
exaly   +3 more sources

Antiangiogenic effects of cucurbitacin-I

Archives of Pharmacal Research, 2014
Cucurbitacin-I is a naturally occurring tetracyclic triterpenoid compound with diverse physiological actions that include inducing apoptosis and blocking cell cycle progression of various cancer cells. However, its antiangiogenic activity has not yet been examined.
Jin-Kyung Kim
exaly   +3 more sources

Home - About - Disclaimer - Privacy